Sutaria Saumya sold $27.6M of THC

Sutaria Saumya (CEO) sold 100,000 shares of TENET HEALTHCARE CORP (THC) at an average of $276.36 ($273.34–$278.90, $27.64M total) across 5 trades over 2026-08-24 to 2026-08-25.

Original reporting
SEC EDGAR · Sutaria Saumya
Published Aug 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 12:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

The CEO's $27.6M share sale may trigger short interest and price volatility.

02

Market read

First disclosure of a sizable insider sell; traders may reassess THC exposure.

03

What to watch

no 10b5‑1 plan, suggesting discretionary timing

Relevance 7/10Novelty 7/10Timing: filing disclosed on 2026‑08‑26 after market close

Background

Form 4 filing reports insider transaction for Tenet Healthcare Corp (THC).

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

CEO Sutaria Saumya sold 100,000 shares for $27.6M, reducing ownership to 433,564 shares.

Expected impact

potential short-term downside pressure

Evidence & confidence

CEO sale of $27M is material for a mid‑cap biotech; market may interpret as negative.

Market effects

may raise concerns for other biotech insiders and affect sector sentiment

limited to US biotech market

low

Counterpoint

sale could be a routine liquidity event, not a confidence signal

Key entities

  • Tenet Healthcare Corp

    Biotech firm listed on Nasdaq under ticker THC

  • Sutaria Saumya

    CEO and director of Tenet Healthcare Corp

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.